BioNano Genomics Inc vs Rockwell Automation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Rockwell Automation trades at $463.56 (market cap $52.27B). The key difference: Rockwell Automation is far larger — about 3959.8× BioNano Genomics Inc's market cap, and Rockwell Automation pays a 1.18% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | ROK | |
|---|---|---|
Market Cap | $13.20M | $52.27B |
Sector | Health | Industrials |
52-Week High | $4.92 | $495.08 |
52-Week Low | $1.09 | $328.67 |
Enterprise Value | $15.81M | $55.90B |
Dividend Yield | — | 1.18% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Rockwell Automation (ROK) trades at $460.45, down 2.47% today, with a neutral technical signal and bullish moving averages. The company shows strong profitability with 48.92% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights leadership in industrial automation and AI integration, including new FactoryTalk software launches and WEF recognition for its Singapore facility.
ROK presents a mixed outlook with solid fundamentals but premium valuation (P/E 47.81). Analyst consensus is cautious with 64% hold ratings, though price targets suggest modest upside to $471.71. Key risks include execution challenges in scaling MES integration and industrial sector volatility. The stock offers growth exposure to industrial automation trends with dividend income support.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →